Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Where are we going with SSRIs?
Autore:
Isaac, M;
Indirizzi:
Univ Hosp, Psychopharmacol Evaluat Unit, London SE13 6LH, England Univ Hosp London England SE13 6LH Evaluat Unit, London SE13 6LH, England
Titolo Testata:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
, volume: 9, anno: 1999, supplemento:, 3
pagine: S101 - S106
SICI:
0924-977X(199907)9:<S101:WAWGWS>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSTTRAUMATIC-STRESS-DISORDER; PLACEBO-CONTROLLED TRIAL; OBSESSIVE-COMPULSIVE DISORDER; GENERALIZED ANXIETY DISORDER; NATIONAL-COMORBIDITY-SURVEY; CORONARY HEART-DISEASE; DOUBLE-BLIND; DEPRESSED-PATIENTS; MAJOR DEPRESSION; MYOCARDIAL-INFARCTION;
Keywords:
selective serotonin reuptake inhibitor; augmentation; pindolol; social anxiety disorder/social phobia; anxiety disorders; depression;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Isaac, M Univ Hosp, Psychopharmacol Evaluat Unit, Ladywell Bldg, London SE13 6LH, England Univ Hosp Ladywell Bldg London England SE13 6LH E13 6LH, England
Citazione:
M. Isaac, "Where are we going with SSRIs?", EUR NEUROPS, 9, 1999, pp. S101-S106

Abstract

During the past decade the selective serotonin reuptake inhibitors (SSRIs)have become established as the treatment of choice for depression. As newer antidepressants become available on the market, it is important to reappraise the position of the SSRIs in the management of depression. This reviewwill address the question: where are we going with the SSRIs? The continued establishment of the SSRIs as first-line treatment for depression will bediscussed, focusing on the more rapid onset of antidepressant efficacy seen with pindolol augmentation and the use of SSRIs for treatment of depression in patients with physical illnesses, particularly ischaemic heart disease. The SSRIs have well-documented efficacy in panic disorder and obsessive-compulsive disorder, and paroxetine has recently been licensed for social anxiety disorder/social phobia in some countries. Results will be presented from studies with the SSRIs in new therapeutic areas, including post-traumatic stress disorder and generalized anxiety disorder. (C) 1999 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 07:28:03